Lenacapavir: First Approval

Teeraananchai S, Chaivooth S, Kerr SJ, et al. Life expectancy after initiation of combination antiretroviral therapy in Thailand. Antivir Ther. 2017;22(5):393–402.

Article  Google Scholar 

Oh KS, Han E. A comparison of medication adherence and viral suppression in antiretroviral treatment-naive patients with HIV/AIDS depending on the drug formulary. PLoS ONE. 2021;16(1): e0245185.

Article  CAS  Google Scholar 

Shubber Z, Mills EJ, Nachega JB, et al. Patient-reported barriers to adherence to antiretroviral therapy: a systematic review and meta-analysis. PLoS Med. 2016;13(11): e1002183.

Article  Google Scholar 

Gilead Sciences Inc. Lenacapavir (Sunlenca®): EU summary of product characteristics. 2022. https://ema.europa.eu/. Accessed 21 Sep 2022.

Gilead Sciences Inc. Gilead announces first regulatory approval for Sunlenca® (lenacapavir), the only twice-yearly HIV treatment option [media release]. 22 Aug 2022. https://www.gilead.com/.

Gilead S. Gilead and Merck announce agreement to jointly develop and commercialize long-acting, investigational treatment combinations of lenacapavir and islatravir in HIV [media release]. 15 Mar 2021. http://www.gilead.com.

Bester SM, Wei G, Zhao H, et al. Structural and mechanistic bases for a potent HIV-1 capsid inhibitor. Science. 2020;370(6514):360–4.

Article  CAS  Google Scholar 

Link JO, Rhee MS, Tse WC, et al. Clinical targeting of HIV capsid protein with a long-acting small molecule. Nature. 2020;584(7822):614–8.

Article  CAS  Google Scholar 

Callebaut C, VanderVeen L, Margot N. Activity and resistance characterization of the HIV capsid inhibitor lenacapavir [abstract no. 128]. In: 28th Conference on Retroviruses and Opportunistic Infections. 2021.

Segal-Maurer S, DeJesus E, Stellbrink HJ, et al. Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection. N Engl J Med. 2022;386(19):1793–803.

Article  CAS  Google Scholar 

Gupta S, Sims J, Brinson C, et al. Lenacapavir as part of a combination regimen in treatment-naive people with HIV: week 54 results [abstract no. 138 plus oral presentation]. In: 29th Conference on Retroviruses and Opportunistic Infections. 2002.

Margot N, Ram R, Rhee M, et al. Absence of lenacapavir (GS-6207) phenotypic resistance in HIV Gag cleavage site mutants and in isolates with resistance to existing drug classes. Antimicrob Agents Chemother. 2021;65(3):e02057-e2120.

Article  CAS  Google Scholar 

Margot N, Naik V, VanderVeen L. Absence of cross-resistance to lenacapavir in HIV entry inhibitor-resistant isolates [abstract no. 508]. In: 29th Conference on Retroviruses and Opportunistic Infections. 2022.

Cilento ME, Ong YT, Tedbury PR, et al. Drug interactions in lenacapavir-based long-acting antiviral combinations. Viruses. 2022;14(6):1202.

Article  CAS  Google Scholar 

Weber E, Graham H, West S, et al. Pharmacokinetics of lenacapavir in participants with severe renal impairment [abstract no. 434]. In: 29th Conference on Retroviruses and Opportunistic Infections. 2022.

Jogiraju V, Begley R, Hindman J, et al. Pharmacokinetics of lenacapavir, an HIV-1 capsid inhibitor, in hepatic impairment [abstract no. 375]. In: 28th Conference on Retroviruses and Opportunistic Infections. 2021.

Ogbuagu O, Segal-Maurer S, Brinson C, et al. Long-acting lenacapavir in people with multi-drug resistant HIV-1: week 52 results [abstract no. P006]. HIV Med. 2022;23(S2):26–7.

Google Scholar 

Stellbrink HJ, DeJesus E, Segal-Maurer S, et al. Subgroup efficacy analyses of long-acting subcutaneous lenacapavir in phase 2/3 in heavily treatment-experienced people with HIV (CAPELLA study). HIV Med. 2021;22:125–6.

Google Scholar 

Gupta SK, Berhe M, Crofoot G, et al. Long-acting subcutaneous lenacapavir dosed every six months as part of a combination regimen in treatment-naive people with HIV: interim 16-week results of a randomized, open-label, phase 2 induction-maintenance study (CALIBRATE) [abstract no. OALB0302 plus presentation]. J Int AIDS Soc. 2021;24:13.

Google Scholar 

留言 (0)

沒有登入
gif